author-photo

Daniel H. Palmer

University of Liverpool
Clatterbridge Cancer Centre NHS Foundation Trust
University of Birmingham

257

Papers

11154

Citations

Citation Trend

Filter By

Papers (257) Sort By

Journal Conference Others

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (53)
SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomised Phase III Controlled Trial of FOLFOX as Second-line Chemotherapy for Advanced Biliary Tract Cancer

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis.

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (3)
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Human Mass Balance and Metabolite Profiling of [14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.

2021 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (1)
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)